XyloCor’s cardiovascular gene therapy XC001 passes Phase 1 with promising results

XyloCor Therapeutics, Inc., a company specializing in the development of gene therapies for cardiovascular diseases, announced that the Phase 1 findings of its clinical trial ... Read More